GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31

Greenwich LifeSciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$15.21+0.66 (+4.54%)

Close on Oct 19, 2026

Market cap: $222.39M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Greenwich LifeSciences has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Greenwich LifeSciences filed with the SEC

Feb 14, 2024, 4:10 PM ET
LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
Other events · EX-99.1 to Form 8-K
Jul 12, 2022, 6:10 AM ET
LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
Other events · EX-99.1 to Form 8-K
Dec 13, 2021, 6:04 AM ET
LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Other events · EX-99.1 to Form 8-K
Nov 10, 2021, 6:52 AM ET
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 10, 2021, 6:52 AM ET
LifeSciences Provides Updated Corporate Presentation and Webcasts
Regulation FD disclosure · EX-99.2 to Form 8-K